- Home
- QTTB vs DYAI Comparison
QTTB vs DYAI Comparison
Compare QTTB & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTTB
- DYAI
- Stock Information
- Founded
- QTTB 2015
- DYAI 1979
- Country
- QTTB United States
- DYAI United States
- Employees
- QTTB N/A
- DYAI N/A
- Industry
- QTTB Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QTTB Health Care
- DYAI Health Care
- Exchange
- QTTB Nasdaq
- DYAI Nasdaq
- Market Cap
- QTTB 26.3M
- DYAI 30.2M
- IPO Year
- QTTB N/A
- DYAI 2004
- Fundamental
- Price
- QTTB $2.01
- DYAI $0.94
- Analyst Decision
- QTTB Hold
- DYAI Strong Buy
- Analyst Count
- QTTB 7
- DYAI 1
- Target Price
- QTTB $12.17
- DYAI $3.00
- AVG Volume (30 Days)
- QTTB 81.9K
- DYAI 111.6K
- Earning Date
- QTTB 11-13-2025
- DYAI 11-12-2025
- Dividend Yield
- QTTB N/A
- DYAI N/A
- EPS Growth
- QTTB N/A
- DYAI N/A
- EPS
- QTTB N/A
- DYAI N/A
- Revenue
- QTTB N/A
- DYAI $3,342,195.00
- Revenue This Year
- QTTB N/A
- DYAI $18.18
- Revenue Next Year
- QTTB N/A
- DYAI $87.65
- P/E Ratio
- QTTB N/A
- DYAI N/A
- Revenue Growth
- QTTB N/A
- DYAI N/A
- 52 Week Low
- QTTB $1.35
- DYAI $0.71
- 52 Week High
- QTTB $28.66
- DYAI $2.20
- Technical
- Relative Strength Index (RSI)
- QTTB 38.52
- DYAI 41.23
- Support Level
- QTTB $1.91
- DYAI $0.85
- Resistance Level
- QTTB $2.42
- DYAI $0.98
- Average True Range (ATR)
- QTTB 0.22
- DYAI 0.08
- MACD
- QTTB -0.06
- DYAI -0.01
- Stochastic Oscillator
- QTTB 13.66
- DYAI 36.21
About QTTB Q32 Bio Inc. Common Stock
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.